Alain R. Thierry

Alain R. Thierry
Born (1959-10-21) 21 October 1959
France
Alma materUniversity of Clermont-Ferrand (France)

University of Montpellier II (france)

Faculty of Médecine, University of Paris-Sud (France)
Scientific career
FieldsGenetics and Cancer Research
WorkplacesGeorgetown University Medical Centre

National Cancer Institute - National Institutes of Health Université de Montpellier

IRCM / INSERM

Alain Thierry (born 21 October 1959) is a French geneticist and cancer researcher. He has been the principal investigator in numerous discoveries in drug delivery innovation[1][2] and application in oncology.[3] He now specializes in the clinical applications of liquid biopsy that exploits circulating DNA as a biomarker, notably in cancer care management.[4][5][6][7] He is currently Director of Research at the INSERM's Cancer Research Institute in Montpellier, France.

Education

Thierry obtained his primary degree in Cellular and Molecular Biology (MSc) at the University of Clermont-Ferrand in France in 1982. In 1986 he completed his PhD in Biochemistry, Cellular and Molecular Pharmacology at the University of Montpellier II. The following year he was awarded the Certificat d'Etudes Supérieures (CES) in Human Biology in Clinical and Experimental Oncology, from the Paris-Sud Faculty of Medicine.

Career

Thierry began his career in the US as a Postdoctoral Fellow (1988–92) at the Lombardi Cancer Centre in the Georgetown University Medical Centre (Washington DC), going on to work there as Adjunct Assistant Professor from 1992 to 1994. From 1992 to 1996 he was also a Visiting Scientist at the Laboratory of Tumor Cell Biology at the National Institutes of Health in Bethesda, where he worked with Dr. Robert C. Gallo, the laboratory's Director.

Returning to France, from 1997 to 2000 he served as Scientific Director at the Biovector Therapeutics company. From 2001 to 2007 he was Associate Professor at Montpellier University's Faculty of Sciences. Since 2008, he has been the Senior Investigator and Director of Research at the INSERM's Cancer Research Institute of Montpellier (IRCM).

Research

Thierry specializes in the clinical application of liquid biopsy that exploits circulating DNA as a biomarker, notably in cancer management care. He has been the principal investigator in numerous discoveries in drug delivery innovation and application in oncology.

It was during his period at Georgetown that he showed the circumvention of multi-drug resistance in tumors through drug delivery.[8] He built on this work at the US National Cancer Institute,[9] developing gene therapy for cancer and HIV,[10][11] in particular the first long term expression of a transgene by systemic administration with a synthetic delivery system.[12]

While at the University of Montpellier, he worked first on the pharmacokinetics of therapeutic vectorized HIV antisense oligonucleotides in primates (2002).[13] He then went on to demonstrate the biomimetic supramolecular auto-organization of DNA in a synthetic complex (2006).[14]

Since 2006, Thierry has focused increasingly on clinical and basic research into the role of circulating DNA (cirDNA), and on its diagnostic potential in oncology.

His team were amongst the first (in April 2020) to suggest NETs as a key player in COVID-19 pathogenesis (2020)[15] and have shown long COVID-19 (COVID post-acute phase syndrome) to be an effect of the persistence of the production of NETs and auto-antibodies.[16] Recently (2022), they have demonstrated cirDNA association with NETs production in cancer and lupus.[17] His recent work revealed the quantitative and qualitative association of NETs with microclots in Long COVID patients.[18][19][20]

Thierry has in recent years also pioneered work on cirDNA fragmentation, proposing potential solutions towards cancer screening through the use of fragmentomics.[21] This builds on earlier work (2011) on the fragmentation levels of cancer patient cirDNA.[22][23]

Most recently, Thierry and his team discovered the presence of circulating extracellular cell-free mitochondria,[24] opening new avenues of research and treatment, for instance mitochondria transplantation.[25]

According to Google Scholar, he has an h-index of 51.[26]

Awards and honors

References

  1. ↑ Thierry, A R; Lunardi-Iskandar, Y; Bryant, J L; Rabinovich, P; Gallo, R C; Mahan, L C (1995-10-10). "Systemic gene therapy: biodistribution and long-term expression of a transgene in mice". Proceedings of the National Academy of Sciences. 92 (21): 9742–9746. Bibcode:1995PNAS...92.9742T. doi:10.1073/pnas.92.21.9742. PMC 40878. PMID 7568209.
  2. ↑ Thierry, Alain R.; Jorgensen, Timothy J.; Forst, Diana; Belli, James A.; Dritschilo, Anatoly; Rahman, Aquilur (1989-11-01). "Multidrug Resistance in Chinese Hamster Cells: Effect of Liposome-Encapsulated Doxorubicin". Cancer Communications. 1 (5): 311–316. doi:10.3727/095535489820874931. ISSN 0955-3541. PMID 2577154.
  3. ↑ Thierry, Alain R.; Vigé, Dominique; Coughlin, Steven S.; Belli, James A.; Dritschilo, Anatoly; Rahman, Aquilur (1993). "Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes". The FASEB Journal. 7 (6): 572–579. doi:10.1096/fasebj.7.6.8097173. ISSN 1530-6860. PMID 8097173.
  4. ↑ Mirandola, Alexia; Kudriavtsev, Andrei; Muñoz, Catalina Isabel Cofre; Navarro, Raquel Comas; Macagno, Marco; Daoud, Saidi; Sanchez, Cynthia; Pastor, Brice; Pisareva, Ekaterina; Marin, Mireia Sanchis; Ruiz, Javier Gonzalo; Piris, Alejandro; Rodriguez, Ariadna Garcia; Gonzalez, Nadia Saoudi; Vivancos, Ana (2024-10-01). "Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer". eBioMedicine. 108 105352. doi:10.1016/j.ebiom.2024.105352. ISSN 2352-3964. PMC 11437914. PMID 39303668.
  5. ↑ Thierry, Alain R.; Pisareva, Ekaterina (2023-10-05). "A New Paradigm of the Origins of Circulating DNA in Patients with Cancer". Cancer Discovery. 13 (10): 2122–2124. doi:10.1158/2159-8290.CD-23-0824. ISSN 2159-8274. PMID 37794839.
  6. ↑ Thierry, A. R.; Messaoudi, S. El; Mollevi, C.; Raoul, J. L.; Guimbaud, R.; Pezet, D.; Artru, P.; Assenat, E.; Borg, C.; Mathonnet, M.; Fouchardière, C. De La; Bouché, O.; Gavoille, C.; Fiess, C.; Auzemery, B. (2017-09-01). "Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment". Annals of Oncology. 28 (9): 2149–2159. doi:10.1093/annonc/mdx330. ISSN 0923-7534. PMID 28911069.
  7. ↑ Thierry, Alain R; Mouliere, Florent; El Messaoudi, Safia; Mollevi, Caroline; Lopez-Crapez, Evelyne; Rolet, Fanny; Gillet, Brigitte; Gongora, Celine; Dechelotte, Pierre; Robert, Bruno; Del Rio, Maguy; Lamy, Pierre-Jean; Bibeau, Frederic; Nouaille, Michelle; Loriot, Virginie (April 2014). "Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA". Nature Medicine. 20 (4): 430–435. doi:10.1038/nm.3511. ISSN 1078-8956. PMID 24658074.
  8. ↑ Thierry, Alain R.; Vigé, Dominique; Coughlin, Steven S.; Belli, James A.; Dritschilo, Anatoly; Rahman, Aquilur (April 1993). "Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes". The FASEB Journal. 7 (6): 572–579. doi:10.1096/fasebj.7.6.8097173. ISSN 0892-6638. PMID 8097173. S2CID 25142393.
  9. ↑ "Kaposi's sarcoma will be initial focus of NCI's Gallo's new outside Institute of Human Virology". pink.pharmaintelligence.informa.com. 5 June 1995.
  10. ↑ nih.gov
  11. ↑ Lunardi-lskandar, Yanto; Bryant, Joseph L.; Zeman, Robert A.; Lam, Victor H.; Samaniego, Felipe; Besnier, Jacques M.; Hermans, Philippe; Thierry, Alain R.; Gill, Parkash; Gallo, Robert C. (May 1995). "Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone". Nature. 375 (6526): 64–68. Bibcode:1995Natur.375...64L. doi:10.1038/375064a0. ISSN 1476-4687. PMID 7723844. S2CID 4352863.
  12. ↑ Thierry, A R; Lunardi-Iskandar, Y; Bryant, J L; Rabinovich, P; Gallo, R C; Mahan, L C (1995-10-10). "Systemic gene therapy: biodistribution and long-term expression of a transgene in mice". Proceedings of the National Academy of Sciences. 92 (21): 9742–9746. Bibcode:1995PNAS...92.9742T. doi:10.1073/pnas.92.21.9742. ISSN 0027-8424. PMC 40878. PMID 7568209.
  13. ↑ Tavitian, Bertrand; Marzabal, Stéphane; Boutet, Valérie; Kühnast, Bertrand; Terrazzino, Salvatore; Moynier, Marinette; Dollé, Frédéric; Deverre, Jean Robert; Thierry, Alain R. (2002-04-01). "Characterization of a Synthetic Anionic Vector for Oligonucleotide Delivery Using in Vivo Whole Body Dynamic Imaging". Pharmaceutical Research. 19 (4): 367–376. doi:10.1023/A:1015133205457. ISSN 1573-904X. PMID 12033366. S2CID 24269784.
  14. ↑ Schmutz, M.; Durand, D.; Debin, A.; Palvadeau, Y.; Etienne, A.; Thierry, A. R. (1999-10-26). "DNA packing in stable lipid complexes designed for gene transfer imitates DNA compaction in bacteriophage". Proceedings of the National Academy of Sciences. 96 (22): 12293–12298. Bibcode:1999PNAS...9612293S. doi:10.1073/pnas.96.22.12293. ISSN 0027-8424. PMC 22910. PMID 10535915.
  15. ↑ Thierry, Alain; Roch, Benoit (2020-04-15). "NETs By-products and Extracellular DNA May Play a Key Role in COVID-19 Pathogenesis: Incidence on Patient Monitoring and Therapy". doi:10.20944/preprints202004.0238.v1. {{cite journal}}: Cite journal requires |journal= (help)
  16. ↑ Pisareva, Ekaterina; Badiou, Stephanie; Mihalovičová, Lucia; Mirandola, Alexia; Pastor, Brice; Kudriavtsev, Andrei; Berger, Marie; Roubille, Camille; Fesler, Pierre; Klouche, Kada; Cristol, Jean-Paul; Thierry, Alain R. (January 2023). "Persistence of neutrophil extracellular traps and anticardiolipin auto-antibodies in post-acute phase COVID-19 patients". Journal of Medical Virology. 95 (1) e28209. doi:10.1002/jmv.28209. ISSN 0146-6615. PMC 9874393. PMID 36226380.
  17. ↑ Pisareva, Ekaterina; Mihalovičová, Lucia; Pastor, Brice; Kudriavtsev, Andrei; Mirandola, Alexia; Mazard, Thibault; Badiou, Stephanie; Maus, Ulrich; Ostermann, Lena; Weinmann-Menke, Julia; Neuberger, Elmo W. I.; Simon, Perikles; Thierry, Alain R. (2022-11-28). "Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA". Genome Medicine. 14 (1): 135. doi:10.1186/s13073-022-01125-8. ISSN 1756-994X. PMC 9702877. PMID 36443816.
  18. ↑ Al Amir Dache, Zahra; Otandault, Amaëlle; Tanos, Rita; Pastor, Brice; Meddeb, Romain; Sanchez, Cynthia; Arena, Giuseppe; Lasorsa, Laurence; Bennett, Andrew; Grange, Thierry; El Messaoudi, Safia; Mazard, Thibault; Prevostel, Corinne; Thierry, Alain R. (2020). "Blood contains circulating cell-free respiratory competent mitochondria". The FASEB Journal. 34 (3): 3616–3630. doi:10.1096/fj.201901917RR. ISSN 1530-6860. PMID 31957088.
  19. ↑ Kapoor, Suman; Mihalovičová, Lucia; Pisareva, Ekaterina; Pastor, Brice; Mirandola, Alexia; Roch, Benoit; Bryant, Joe; Princy, Anna Philip; Chouaib, Salem; Thierry, Alain Roger (May 2024). "Association of vascular netosis with COVID-19 severity in asymptomatic and symptomatic patients". iScience. 27 (5) 109573. Bibcode:2024iSci...27j9573K. doi:10.1016/j.isci.2024.109573. ISSN 2589-0042. PMC 11039348. PMID 38660409.
  20. ↑ Thierry, Alain R.; Usher, Tom; Sanchez, Cynthia; Turner, Simone; Venter, Chantelle; Pastor, Brice; Waters, Maxine; Thompson, Anel; Mirandola, Alexia; Pisareva, Ekaterina; Prevostel, Corinne; Laubscher, Gert J.; Kell, Douglas B.; Pretorius, Etheresia (2025). "Circulating Microclots Are Structurally Associated With Neutrophil Extracellular Traps and Their Amounts Are Elevated in Long COVID Patients". Journal of Medical Virology. 97 (10) e70613. doi:10.1002/jmv.70613. ISSN 1096-9071. PMC 12489976. PMID 41036702.
  21. ↑ Thierry, A.R. (January 2023). "Circulating DNA fragmentomics and cancer screening". Cell Genomics. 3 (1) 100242. doi:10.1016/j.xgen.2022.100242. PMC 9903826. PMID 36777187.
  22. ↑ Sanchez, Cynthia; Roch, Benoit; Mazard, Thibault; Blache, Philippe; Dache, Zahra Al Amir; Pastor, Brice; Pisareva, Ekaterina; Tanos, Rita; Thierry, Alain R. (2021-04-08). "Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics". JCI Insight. 6 (7) e144561. doi:10.1172/jci.insight.144561. ISSN 0021-9738. PMC 8119211. PMID 33571170.
  23. ↑ Mouliere, Florent; Robert, Bruno; Arnau Peyrotte, Erika; Del Rio, Maguy; Ychou, Marc; Molina, Franck; Gongora, Celine; Thierry, Alain R. (2011-09-06). Lee, Terence (ed.). "High Fragmentation Characterizes Tumour-Derived Circulating DNA". PLOS ONE. 6 (9) e23418. Bibcode:2011PLoSO...623418M. doi:10.1371/journal.pone.0023418. ISSN 1932-6203. PMC 3167805. PMID 21909401.
  24. ↑ Roch, Benoit; Pisareva, Ekaterina; Mirandola, Alexia; Sanchez, Cynthia; Pastor, Brice; Tanos, Rita; Frayssinoux, Florence; Diab-Assaf, Mona; Anker, Philippe; Al Amir Dache, Zahra; Thierry, Alain R. (January 2024). "Impact of platelet activation on the release of cell-free mitochondria and circulating mitochondrial DNA". Clinica Chimica Acta. 553 117711. doi:10.1016/j.cca.2023.117711. PMID 38101467.
  25. ↑ Brestoff, Jonathan R.; Singh, Keshav K.; Aquilano, Katia; Becker, Lance B.; Berridge, Michael V.; Boilard, Eric; Caicedo, Andrés; Crewe, Clair; Enríquez, José Antonio; Gao, Jianqing; Gustafsson, Åsa B.; Hayakawa, Kazuhide; Khoury, Maroun; Lee, Yun-Sil; Lettieri-Barbato, Daniele (2025-01-16). "Recommendations for mitochondria transfer and transplantation nomenclature and characterization". Nature Metabolism. 7 (1): 53–67. doi:10.1038/s42255-024-01200-x. ISSN 2522-5812. PMID 39820558.
  26. ↑ "alain THIERRY". scholar.google.fr. Retrieved 2023-05-04.
  27. ↑ "Cinq chercheuses et chercheurs reçoivent les Prix 2021 de l'Innovation "Montpellier Université d'Excellence" - Université de Montpellier". umontpellier.fr (in French). 16 December 2021. Retrieved 2023-05-04.
  28. ↑ "La Fondation pour l'Innovation Thérapeutique Béatrice Denys: récompenses 2016".
  29. ↑ "Prix de l'Innovation Therapeutique Beatrice Denys". Siric. 24 June 2016.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.